BioNTech SE (BNTX.O) shares fell about 10% in U.S. premarket trading after the
company said it has terminated its Phase II trial of Cevumeran, a cancer
immunotherapy.
2026-08-28
BioNTech SE (BNTX.O) shares fell about 10% in U.S. premarket trading after the
company said it has terminated its Phase II trial of Cevumeran, a cancer
immunotherapy.